FDA letter on labeling and dosing risks with compounded GLP-1 vials
The FDA's Office of Compounding Quality and Compliance issued a letter to the Federation of State Medical Boards (FSMB) on August 12, 2026 highlighting concerns regarding compounded GLP-1 medications that are dispensed in multi-dose vials. The FDA asked the FSMB to share this information with state medical boards to increase awareness of dosing and safety concerns.